Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
Panelists discuss the protocol for long-term monitoring of patients who receive chimeric antigen receptor (CAR) T-cell therapy, focusing on relapse prevention and overall health, as well as the impact of CAR T-cell therapy on long-term management of patients with standard-risk disease, including additional steps to monitor disease progression and ongoing support in the months and years following treatment.
EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment
EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges
EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience
EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy
EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
What is the protocol for long-term monitoring of patients who receive chimeric antigen receptor (CAR) T-cell therapy in their treatment journey?
What specific factors do you focus on in terms of relapse prevention or overall health in these patients?
Dr Castaneda: Ask Jammie:
How does the use of CAR T-cell therapy affect your long-term management of patients with standard-risk disease? What additional steps do you take to monitor their disease progression?
Dr Castaneda: Ask Jammie:
How do you continue to support patients in the months and years following CAR T-cell therapy?
